

## ASX Announcement

### Prof. Borje Andersson resigns from Board to focus on CMO and CAB roles

- Professor Borje Andersson resigns as an Executive Director of Race
- Role change follows Prof. Andersson's appointments as Chief Medical Officer (October 2020) and Clinical Advisory Board Chair (December 2019)
- Change enables Prof. Andersson to focus fully on Race's clinical programs

---

**10 December 2020** – Race Oncology Limited (**Race** or the **Company**) (ASX: RAC) advises that Professor Borje Andersson has resigned as an Executive Director in order to focus on his roles of Chief Medical Officer and Chair of the Race Clinical Advisory Board.

Prof. Andersson joined the Race Board as Non-Executive Director on 28 January 2020 prior to his appointment to the executive team (02 October 2020).

In addition, the options issued to Prof. Andersson on 28 January 2020 will continue to vest in accordance with their terms.

Race's Chairman, Dr John Cullity commented:

*"Borje has made an outstanding contribution to the Board during his tenure. Given the speed at which our clinical program is moving and the part-time nature of his role, it now makes sense for Borje's efforts to be fully applied to our goal of progressing Bisantrone's clinical programmes. On behalf of my fellow Directors, I sincerely thank Borje for his time on the Board."*

-ENDS-

### About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrone.

Bisantrone is a potent inhibitor of the Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Bisantrone as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Bisantrone as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.



Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Bisantrene. See more at [www.raceoncology.com](http://www.raceoncology.com).

**Release authorised by:**

Phil Lynch, CEO/MD on behalf  
of the Race Board of Directors  
[phillip.lynch@raceoncology.com](mailto:phillip.lynch@raceoncology.com)

**Media contact:**

Jane Lowe  
+61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)